title: Oral sustained-release cisplatin capsule.
abstract: An oral sustained-release cisplatin preparation was prepared by combining microporous water-insoluble pharmaceutical polymer, ethylcellulose, a membrane and a gel-forming polymer, poly(acrylic) acid (Carbopol). As cisplatin is an extremely hydrophilic and small compound, it was difficult to control the release rate solely by the micropores on the ethylcellulose capsule. To retain cisplatin within the capsule, gel-forming polymer was formulated inside the capsule. The release rate of cisplatin was dependent both on the number of micropores of the capsule and the formulated amount of Carbopol. The number of micropores ranged from 20 and 30 to 60, and the formulated amount of Carbopol varied from 15 to 100 mg. In-vitro release experiments suggested that the release rate decreased as the formulated amount of Carbopol increased when the pore number was 60 and 30. However, when pore number was decreased to 20, the effect of the amount of Carbopol was not clearly observed. In the in-vivo study using rabbits, the sustained-release cisplatin capsule was evaluated in comparison with solution after oral administration of 20 mg drug. With the pore number of 60, Cmax was 0.46 +/- 0.02 microgram mL-1 at 4 h and thereafter serum concentrations declined rapidly. When the pore number was 30, serum cisplatin level-time profiles showed long-acting patterns and AUC was reversely correlated with the formulated amount of Carbopol. Cmax and tmax were 0.41 +/- 0.02 microgram mL-1 and 3.33 +/- 0.88 h, respectively and 0.23 +/- 0.01 microgram mL-1 was obtained at 24 h after oral administration of capsule having 30 pores and 15 mg of Carbopol. We conclude that the possibility of developing an oral sustained-release cisplatin preparation is feasible.
authors.affiliation: Department of Pharmaceutics and Pharmacokinetics, Kyoto Pharmaceutical University, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Houjou
authors.forename: K
authors.initials: K
authors.lastname: Nakano
authors.forename: O
authors.initials: O
authors.lastname: Ike
authors.forename: H
authors.initials: H
authors.lastname: Wada
authors.forename: S
authors.initials: S
authors.lastname: Hitomi
authors.forename: Y
authors.initials: Y
authors.lastname: Shinmi
authors.forename: N
authors.initials: N
authors.lastname: Danno
authors.forename: Y
authors.initials: Y
authors.lastname: Yoshikawa
authors.forename: K
authors.initials: K
authors.lastname: Takada
mesh_terms: D000180:Acrylic Resins; D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D001682:Biological Availability; D002214:Capsules; D002482:Cellulose / Q000031:analogs & derivatives; D002945:Cisplatin / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D007262:Infusions, Intravenous; D008297:Male; D011145:Polyvinyls; D011817:Rabbits; D012995:Solubility
chemical_list: D000180:Acrylic Resins; D000970:Antineoplastic Agents; D002214:Capsules; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D011145:Polyvinyls; C006912:carboxypolymethylene; C013517:ethyl cellulose; D002482:Cellulose; D002945:Cisplatin